Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105:1811-9.
02.03.2010
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
02.03.2010
Am J Gastroenterol 2010; 105:1811-9
Jürgens Matthias, Ochsenkühn Thomas, Glas Jürgen, Göke Burkhard, Lohse Peter, Tillack Cornelia, Schnitzler Fabian, Stallhofer Johannes, Pfennig Simone, Beigel Florian, Wetzke Martin, Wagner Johanna, Seiderer Julia, Weidinger Maria, Hartl Franziska, Laubender Rüdiger P, Brand Stephan
Weiter
